title: Bispecific antibodies in cancer immunotherapy.
abstract: Cancer immunotherapy has recently generated much excitement after the continuing success of the immunomodulating anti-CTLA-4 and anti-PD-1 antibodies against various types of cancers. Aside from these immunomodulating antibodies, bispecific antibodies, chimeric antigen receptor T cells, and other technologies are being actively studied. Among the various approaches to cancer immunotherapy, 2 bispecific antibodies are currently approved for patient care. Many more bispecific antibodies are now in various phases of clinical development and will become the next generation of antibody-based therapies. Further understanding of immunology and advances in protein engineering will help to generate a greater variety of bispecific antibodies to fight cancer. Here, we focus on bispecific antibodies that recruit immune cells to engage and kill tumor cells.
authors.affiliation: a School of Pharmaceutical Sciences, Sun Yat-Sen University , Guangzhou , China.|b Center for Cellular & Structural Biology, Sun Yat-Sen University , Guangzhou , China.
authors.forename: Siqi
authors.initials: S
authors.lastname: Chen
authors.affiliation: a School of Pharmaceutical Sciences, Sun Yat-Sen University , Guangzhou , China.|b Center for Cellular & Structural Biology, Sun Yat-Sen University , Guangzhou , China.
authors.forename: Jing
authors.initials: J
authors.lastname: Li
authors.affiliation: a School of Pharmaceutical Sciences, Sun Yat-Sen University , Guangzhou , China.|b Center for Cellular & Structural Biology, Sun Yat-Sen University , Guangzhou , China.
authors.forename: Qing
authors.initials: Q
authors.lastname: Li
authors.affiliation: a School of Pharmaceutical Sciences, Sun Yat-Sen University , Guangzhou , China.|b Center for Cellular & Structural Biology, Sun Yat-Sen University , Guangzhou , China.
authors.forename: Zhong
authors.initials: Z
authors.lastname: Wang
mesh_terms: D018033:Antibodies, Bispecific / Q000008:administration & dosage*; D017277:Drug Approval; D055808:Drug Discovery / Q000639:trends; D006801:Humans; D007155:Immunologic Factors / Q000008:administration & dosage*; D007167:Immunotherapy / Q000379:methods*; D009369:Neoplasms / Q000628:therapy*
chemical_list: D018033:Antibodies, Bispecific; D007155:Immunologic Factors
keywords: NK cells; T cells; bispecific antibody; cancer; heterodimerization; immunotherapy; scFv; single domain antibody